Michael T Eadon, Marc B Rosenman, Pengyue Zhang, Cathy R Fulton, John T Callaghan, Ann M Holmes, Kenneth D Levy, Samir K Gupta, David M Haas, Raj Vuppalanchi, Eric A Benson, Rolf P Kreutz, Emma M Tillman, Tyler Shugg, Rebecca C Pierson, Brandon T Gufford, Victoria M Pratt, Yong Zang, Zeruesenay Desta, Paul R Dexter, Todd C Skaar
Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden. Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of this INGENIOUS trial (NCT02297126) analysis was to determine whether conducting and reporting pharmacogenetic panel testing impacts ADE frequency. The trial was a pragmatic, randomized controlled clinical trial, adapted as a propensity matched analysis in individuals (N = 2612) receiving a new prescription for one or more of 26 pharmacogenetic-actionable drugs across a community safety-net and academic health system...
September 9, 2023: Pharmacogenomics Journal